Altiva

Quick links to important sections

Altiva

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Altiva

Quick Facts

Property Description
Active ingredient Fexofenadine Hydrochloride
Form Oral Tablet, Capsule, Suspension
Pharmacological class H1-Antihistamine (Second-Generation)
General purpose Relief of allergic discomfort
Origin Synthetic compound (Active metabolite)

What is Altiva and Its Classification as a Second-Generation Antihistamine?

Altiva is a medication whose core component is Fexofenadine Hydrochloride, placing it within the therapeutic group of agents used to manage immune system responses, commonly known as allergic conditions. The drug's classification as a second-generation antihistamine is key to its therapeutic profile. The drug is classified as a selective peripheral H1-receptor antagonist and its use in treating allergy symptoms is supported by pharmacological studies.

The chemical identity of Fexofenadine is notable as a synthetic compound and the active metabolic derivative of the older drug, terfenadine. This positioning within the H1-Antihistaminics class signifies that Altiva is engineered to act as a selective peripheral H1-receptor antagonist. Pharmacological studies have consistently supported the compound's high specificity for the H1 receptor compared to other biological targets.


Altiva's Composition, Forms, and Non-Sedating Characteristic

Altiva is a single-ingredient product available in several oral dosage forms, including standard tablets, capsules, and a suspension, allowing for systemic administration. The preparation's most notable characteristic is its non-sedating nature. This effect is achieved because Fexofenadine is designed to be minimally lipophilic, which prevents the molecule from significantly crossing the blood-brain barrier. This characteristic ensures that the medicine provides relief without the side effect of causing typical drowsiness.

The availability of forms like the oral suspension makes it suitable for use across diverse patient groups, including specific pediatric populations. By maintaining targeted action on peripheral receptors, Fexofenadine ensures effective relief while supporting the patient's capacity for alertness and focus.


What is the General Purpose of Altiva (Fexofenadine)?

The general purpose of Altiva is to counteract the physical manifestations triggered by the release of histamine in the body, which occurs during an allergic reaction. By functioning as a high-affinity H1-receptor antagonist, the medication directly intervenes in the chemical cascade that produces common allergy discomforts.

This systemic action provides relief by diminishing the overall intensity of the body's response to allergens. Altiva's fundamental benefit is its capacity to help reduce the generalized discomforts associated with various allergic conditions, often used in a neutral use scenario where an individual needs to manage seasonal allergy symptoms without impairment during a typical workday.

What side effects are possible with Altiva?

Possible Side Effects and Safety Information

The safety profile of Altiva is formally documented in regulatory health agency records, classifying adverse reactions by frequency and highlighting critical restrictions for use.

Adverse Reaction Scope

Category Documented Adverse Reactions (Examples)
Common (ge 1/100 people) Headache, drowsiness/fatigue, dizziness, nausea
Uncommon / Rare Dry mouth, painful menstrual bleeding, back pain, nervousness, trouble sleeping, rash

Serious Adverse Reactions (Label-Documented): Immediate medical attention is required for signs of serious allergic reaction (anaphylaxis), including swelling of the face, lips, tongue, or throat, and difficulty breathing.

System-Organ Classes Involved: Adverse reactions are documented across several system classes, including Nervous System Disorders (headache, dizziness, drowsiness) and Gastrointestinal Disorders (nausea, dry mouth).

Population-Specific Safety Considerations

  • Pediatric Patients: Safety and effectiveness have not been established in children younger than 6 months or 12 years (depending on the specific formulation and regulatory source).
  • Geriatric Patients: Caution is advised, as older patients may be more susceptible to side effects, particularly those with age-related reduced kidney function.
  • Kidney Impairment: Use requires caution, and a dose adjustment may be necessary due to reduced drug clearance in patients with impaired kidney function.

Safety-Related Restrictions or Limitations

  • Contraindication: Do not use if there is a known hypersensitivity or allergy to the active ingredient, fexofenadine, or any of its components.
  • Drug/Food Interactions: Regulatory labels advise against consuming Altiva with fruit juices (such as grapefruit, orange, or apple), as this may reduce the medicine's absorption and effect. Antacids containing aluminum or magnesium should also be avoided within two hours of taking Altiva, as they can also interfere with absorption.

Connection to the Overall Safety Profile: The official safety profile organizes the medicine's risks by frequency to establish patient expectations for common, non-severe side effects, while simultaneously utilizing specific warnings to prominently call attention to rare but severe reactions and critical restrictions, such as use in individuals with kidney impairment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Altiva


Overdose scope

Documented overdose presentations:

  • Overdose reports for Fexofenadine Hydrochloride are infrequent and contain limited information.
  • Manifestations that have been reported include dizziness, drowsiness, dry mouth, and fatigue.

Physiological systems affected (as stated in label):

  • Reported symptoms involve central nervous system effects (drowsiness, dizziness).
  • The elimination half-life may be prolonged in patients with renal impairment.

Dose-related or exposure-related factors (if applicable):

  • The maximum tolerated dose of the drug has not been established.

Population-specific overdose notes (if applicable):

  • Elimination half-life may be prolonged in patients with renal impairment.

Emergency-response statements (as written in official documents):

  • In the event of overdose, consider standard measures to remove any unabsorbed drug.
  • Symptomatic and supportive treatment is recommended.

When immediate medical help is required (label-derived phrasing only):

  • Contact a Poison Control Center right away or seek emergency medical attention.

Overdose classifications (high-level)

Severity classification (as defined in official documents):

  • Overdose reports are described as infrequent.

Regulatory basis (EMA / FDA / etc.):

  • FDA and EMA regulatory documents define this profile.

Overdose-context constraints (as defined in official documents):

  • No specific antidote is known.
  • Haemodialysis does not effectively remove the drug.

Resulting overdose structure

Official overdose statements:

  • Overdose may present with symptoms including dizziness, drowsiness, fatigue, and dry mouth.
  • In case of suspected overdose, contact a Poison Control Center right away or seek emergency medical attention.
  • Treatment is primarily symptomatic and supportive, and standard measures should be considered to remove any unabsorbed product.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by listing the expected manifestations, such as drowsiness and fatigue, which necessitate prompt action. Given the absence of a specific antidote, regulatory authorities mandate that urgent medical help be sought to ensure the application of symptomatic and supportive treatment and the appropriate removal of unabsorbed drug. The profile acknowledges that overdose reports are infrequent.

Therapeutic Uses of Altiva

What Altiva Treats: Main Uses and Benefits

Altiva is commonly used to help with symptoms related to heightened physiological activity associated with Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria. The medication is commonly used across conditions presenting with recurrent or episodic manifestations. It is primarily useful for managing symptoms that interfere with daily comfort, such as persistent sneezing, runny nose (rhinorrhea), intense itching (pruritus) of the nose, throat, or skin, and accompanying ocular symptoms like watery eyes.

The therapeutic benefit supports the patient during difficult episodes. The non-sedating profile assists with maintaining functional stability when symptoms are more noticeable, supporting general well-being. This feature is relevant in clinical settings where patients may assist with management of discomfort without impairment.

“This medication helps ease the overall symptom burden during periods of heightened discomfort.”


Quick Fact: Relief for Allergic Discomfort

Symptom Domain Relief Focus
Seasonal Helps address symptoms that become more disruptive during flare-ups
Chronic Applied in situations where symptoms create noticeable physiological strain
Functional Supports general well-being during symptomatic phases

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Altiva — Official Regulatory Information

Official regulatory documents define the population eligibility for Altiva (Fexofenadine) by setting absolute exclusions and conditional use requirements across specific groups.


Eligibility Scope

  • Populations for whom use is allowed (as stated in label): Adults and adolescents aged 12 years and over. Use is also approved in children as young as 6 months for specific indications and dosage forms (e.g., oral suspension for Chronic Idiopathic Urticaria in the US).

  • Populations for whom use is contraindicated: Patients with known hypersensitivity to Fexofenadine Hydrochloride or to any ingredient in the formulation. This is the single absolute contraindication.

  • Age-related eligibility rules: Safety and effectiveness have not been established in children younger than 6 months. For older adults (aged 65 years and over), use should be with caution, primarily due to the increased possibility of age-related decreased kidney function.

  • Condition-specific eligibility rules: Use is conditional for patients with decreased renal function (kidney impairment), as higher plasma levels are observed. Regulatory agencies require that patients with impaired kidney function receive a reduced starting dose. Although dose adjustment is generally not necessary for hepatic impairment, use with caution is advised.

  • Pregnancy and lactation eligibility status (if explicitly documented): Use should not be used during pregnancy unless clearly necessary. Similarly, the medicine is not recommended for mothers who are breastfeeding.


Resulting Eligibility Structure

Official eligibility statements:

  • Fexofenadine is absolutely contraindicated in individuals with known hypersensitivity.
  • The medicine is approved for use in adults and children 6 months of age and older, with eligibility for specific ages dependent on the dosage form and approved indication.
  • Use is restricted in populations with decreased renal function, requiring dose consideration to prevent accumulation.
  • The drug is not recommended during pregnancy or while breastfeeding.

What should I know about interactions with other medicines?

Altiva Interactions with other medicines and products

The official interaction profile of Altiva (Fexofenadine Hydrochloride) is primarily defined by pharmacokinetic interactions related to drug transport, not metabolism. The medicine undergoes negligible hepatic metabolism and is therefore formally excluded from clinically significant interactions mediated by the cytochrome P450 (CYP) enzyme system. No specific drug-drug combination is formally listed as a contraindication.

Altiva is a substrate for drug transporters, including P-glycoprotein (P-gp) and Organic Anion Transporting Polypeptides (OATP). Co-administration with certain substances that inhibit these transporters may result in documented changes in plasma exposure. For example, co-administration with Erythromycin or Ketoconazole is officially documented to increase the systemic concentration of Fexofenadine.

Two key administration constraints are documented to prevent reduced bioavailability:

  • Antacids: The concurrent use of antacids containing aluminum and magnesium hydroxide is documented to reduce Fexofenadine absorption. Official regulatory guidance requires a minimum separation of 2 hours between the administration of Altiva and these antacids.
  • Fruit Juices: Consumption of specific fruit juices (Grapefruit, Orange, or Apple) is documented to reduce the medicine's bioavailability, likely by inhibiting OATP transporters in the gastrointestinal tract. Altiva must be taken with water only.

Finally, an interaction-related consideration exists for renal impairment: official data confirms that patients with kidney disease exhibit increased plasma levels and a prolonged elimination half-life due to slower clearance.

Mechanism of Action

Selective Peripheral H1-Receptor Antagonism

The core mechanism involves the Histamine H1-receptor, the primary biological target. Fexofenadine acts as a selective competitive antagonist, occupying the H1 receptor site to prevent the binding and subsequent activation by naturally released histamine. This targeted interaction limits the initial molecular steps of the histamine-mediated inflammatory cascade, which results in the inhibition of downstream physiological signaling.


Interruption of Vascular and Neural Responses

By blocking H1-receptors, the drug interrupts the downstream signaling that regulates vascular permeability and peripheral sensory nerves. H1 receptor blockade reduces the signaling that increases capillary wall permeability, thereby modulating fluid exudation into tissues. Simultaneously, it reduces the excitation signals on peripheral sensory nerve endings, which modulate sensory nerve excitability and efferent reflex signaling. This collective action modulates signal transduction across the two primary target systems: the vasculature and peripheral nerves.


Mechanistic Exclusion from the Central Nervous System

A key feature of the drug's mechanism is its peripheral-only activity. Due to its minimal lipophilicity, Fexofenadine is restricted from crossing the blood-brain barrier (BBB). This exclusion mechanism prevents the molecule from engaging H1 receptors within the central nervous system (CNS) that are involved in regulating wakefulness. The exclusion results in the central H1 receptor pathways remaining functionally accessible.

Dosage and Administration Information

Official Administration Guidelines for Altiva

Altiva (Fexofenadine Hydrochloride) is a medicine intended strictly for oral administration, available in several dosage forms including tablets and oral suspension. The specific usage patterns are defined based on age and the presence of renal impairment.


Standardized Dosing and Frequency

Patient Population Recommended Regimen (Fexofenadine HCl) Dosing Frequency
Adults (ge 12 Years) 180 mg or 60 mg Once Daily (QD) or Twice Daily (BID)
Pediatric (6 to 11 Years) 30 mg Twice Daily (BID)

Administration Conditions and Restrictions

Tablets should be taken with water to ensure proper delivery. Usage instructions require the separation of Altiva from certain substances to prevent reduced absorption:

  • Antacids: The product should not be taken at the same time as antacids that contain aluminum or magnesium. It is advised to separate the administration by approximately two hours.
  • Fruit Juices: Avoid taking this medicine with fruit juices, such as grapefruit, apple, or orange juice, as these may reduce the bioavailability of the active ingredient.

For patients with a diagnosed decreased renal function (kidney impairment), the standard dosing schedule is modified. The recommended starting dose for adults (ge 12 years) with renal impairment is 60 mg once daily, which constitutes a reduction from the maximum standard dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Altiva

Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research exploring the study of Altiva in the context of Seasonal Allergic Rhinitis (SAR), commonly known as hay fever, is available. The foundation is built upon multiple studies, including numerous short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, focusing on outcomes related to physical discomfort such as sneezing, runny nose, ocular symptoms, and itchy nose/throat.

These studies, conducted during periods of increased symptom activity, evaluated the combined and individual symptom scores across the observed populations. The studies described patterns observed in the measured symptom outcomes during the short study period. Data from systematic reviews examined the consistency of findings across studies for specific individual symptoms. Follow-up durations were typically limited to about two weeks in core efficacy studies.


Evidence for Use in Chronic Idiopathic Urticaria (CIU)

Research exploring the study of Altiva in the context of Chronic Idiopathic Urticaria (CIU), or persistent hives, is also available. The evidence base here includes RCTs and observational settings, often conducted over approximately four weeks. Research examined outcomes related to systemic or functional imbalance, specifically focusing on measuring changes in the severity of itching (pruritus) and the number of wheals (hives).

Studies examined patterns observed in the outcomes linked to irritative states over the assessed time intervals. Outcomes regarding the results of increased doses in patients not responding to the standard dose were mixed. Long-term effects are not fully established by high-quality, controlled trials; data for the maintenance of relief beyond the four-week study periods are still emerging, largely relying on observational data.


Understanding Evidence in Specific Patient Groups

Research exploring the study of Altiva in populations beyond general adult groups, specifically in children and adolescents, has been conducted. Specific research examined children aged six years and older for the seasonal allergy indication. Findings describe group patterns related to how symptoms evolved in the observed child populations over the study period. However, data for certain groups remain insufficient, particularly for very young children (under six years of age).

Frequently Asked Questions (FAQ)

Common questions about Altiva (FAQ)

Q: Can Altiva cause drowsiness, and if so, how common is it?

A: While Altiva is classified as a non-sedating second-generation antihistamine, official regulatory documents list drowsiness or fatigue as a common side effect, occurring in 1% to 10% of patients in clinical trials. It is important to know that individual responses to the medicine can vary.

Q: Why do doctors often choose Altiva over similar older medications?

A: Regulatory documents describe the medicine’s mechanism of action, highlighting its reduced ability to penetrate the blood-brain barrier. This key feature helps minimize engagement with brain receptors that regulate wakefulness, which helps reduce the sedative side effects commonly associated with older (first-generation) antihistamine agents.

Q: Why does Altiva need to be taken at the same time every day?

A: Official information indicates that this drug has a prolonged elimination half-life, meaning it takes time for the medicine to be processed and leave the body. Taking it consistently helps maintain a steady level of the medicine in your system, which is intended to support symptom management throughout the dosing period.

Q: Are there any restrictions on driving or operating machinery while taking Altiva?

A: While the medicine is generally considered non-drowsy, official guidance suggests that a few people may still be impaired. Because individual responses can vary, official guidance suggests assessing one's personal response to the medication before engaging in activities that require full attention, such as driving or operating machinery.

Q: Can Altiva be taken on an empty stomach?

A: Regulatory instructions emphasize that the tablet should be taken with water and specifically warn against taking it with fruit juices (such as grapefruit, orange, or apple) or antacids. The lack of an explicit instruction regarding food intake suggests that this condition is not a primary concern, provided the critical restrictions are followed.

Q: How quickly does Altiva start to work?

A: Studies and official information indicate that the drug exhibits a measurable antihistamine effect, such as a reduction in symptom scores for seasonal allergies, within 60 minutes following a single dose. This indicates the antihistamine effect begins soon after administration.

Q: Does Altiva interact with common over-the-counter pain relievers?

A: Government health guidance documents, such as those published by the NHS, indicate that common pain relievers like paracetamol or ibuprofen can generally be taken with this medicine. However, verifying the use of any combination of medicines with a healthcare professional is recommended.

Q: Is it normal to feel a bit restless when starting Altiva?

A: Official adverse reaction reports list nervousness as an uncommon side effect. Given the uncommon classification, this feeling is not among the most typical initial responses to the medication, although it has been reported in clinical trials.

Q: Can Altiva be taken while pregnant or breastfeeding?

A: Official regulatory documents state that the medicine should not be used during pregnancy unless clearly necessary. Similarly, it is not recommended for mothers who are breastfeeding, as the drug is known to pass into breast milk.

Q: What's the difference between Altiva and cetirizine?

A: Regulatory documents classify both as second-generation antihistamines, meaning they share the goal of avoiding heavy sedation. However, official information notes differences such as approved dosing frequencies and that the non-sedating properties of Altiva's active ingredient may be less variable in their non-sedating profile than those of cetirizine.

Q: Are there long-term side effects associated with daily use of Altiva?

A: The known side effects of the medicine are classified by how frequently they occur. However, because published regulatory trials for establishing efficacy are typically short-term (e.g., a few weeks), the safety and long-term effects over years of daily use are not fully established by high-quality, controlled studies.

Q: What should I do if I forget to take my Altiva dose?

A: Official drug instructions indicate that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the instructions advise skipping the missed dose and continuing the regular schedule. Regulatory guidance warns against taking a double dose.

Q: Does Altiva interact with alcohol, and what are the risks?

A: The interaction between Altiva and alcohol is typically classified as moderate. While Altiva is a non-sedating drug, combining it with alcohol may increase the risk of side effects such as dizziness or drowsiness in some individuals.

Q: Can Altiva worsen anxiety or cause mood changes?

A: Clinical trial reports include nervousness and trouble sleeping (insomnia) in the list of possible side effects. However, official product labels and warnings do not generally include explicit statements or reports of the medicine causing generalized anxiety or significant mood changes.

Q: Can Altiva be used for chronic conditions, or is it only for acute relief?

A: Studies and official information indicate that the medicine is approved for the treatment of symptoms associated with both Seasonal Allergic Rhinitis (SAR), which may be acute, and Chronic Idiopathic Urticaria (CIU), which is defined as a persistent or chronic condition.

Q: Why do some people report feeling dry mouth on Altiva?

A: This drug’s active ingredient is classified as non-anticholinergic, meaning it does not block the receptors typically responsible for causing dry mouth like older antihistamines. Despite this, dry mouth is still listed in official documents as a reported adverse reaction that occurred during clinical trials.

Q: Can Altiva be taken with flu or cold medicine?

A: Regulatory documents indicate that caution is warranted when considering combining this medicine with other drugs that may independently cause central nervous system side effects like dizziness or drowsiness. Many common cold and flu medicines contain such ingredients, so combining them may increase these specific side effects.

Q: What should I do if I experience unexpected side effects from Altiva?

A: If signs of a serious allergic reaction occur, such as swelling of the face, tongue, or difficulty breathing, immediate medical attention should be sought. For any other unexpected or concerning side effects, official guidance advises contacting a healthcare provider right away.

Q: How soon after stopping Altiva do the effects wear off?

A: The medicine is known to have a relatively long duration of action, with an average plasma elimination half-life of approximately 14 hours. This means that it takes about five half-lives for the drug to be largely cleared from the body, and its effects will gradually wear off over that time.

Q: What is the difference between Altiva and loratadine?

A: Both are classified as second-generation antihistamines with non-sedating properties. Official information notes that Altiva's active component undergoes negligible hepatic metabolism (it is hardly processed by the liver), whereas loratadine is metabolized in the liver, which is a key difference in their pharmacological profiles.

How should Altiva be stored and disposed of?

Storage and Disposal Instructions for Altiva (Fexofenadine)

Altiva must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), protected from both excessive heat and moisture. It is essential to keep the medicine in its original container, tightly closed, and out of the sight and reach of children.

Handling and Disposal

Do not freeze the product. The official label advises that any unused oral suspension should be discarded after a specific period (typically 60 days) once opened. Disposal of unused or expired Altiva should follow regulatory guidelines, preferably utilizing a drug take-back program. Otherwise, it must be prepared for household trash by mixing it with an undesirable substance and placing it in a sealed container; do not flush this medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Altiva found in:

A-Z Index: